InvestorNews.com is pleased to announce an upcoming InvestorTalk scheduled for tomorrow, Tuesday, March 31, 2026, at 9:00 AM EST, featuring Brent Willis, President, CEO, and Director, Voyageur Pharmaceuticals Ltd. (TSXV: VM). To participate in this engaging discussion, please email [email protected] to RSVP.
Voyageur is focused on developing barium and iodine Active Pharmaceutical Ingredients (API) and imaging contrast agents. The Company is advancing five Health Canada-licensed barium contrast products and plans to partner with third-party GMP pharmaceutical manufacturers in Canada to generate initial cash flow and secure global regulatory validation. Over time, Voyageur aims to transition into a high-margin domestic manufacturer of radiology drugs. Central to its strategy is its 100% owned Frances Creek barium sulfate project, which hosts high-grade material suitable for pharmaceutical use. Voyageur’s vertically integrated approach—from raw material sourcing to final product—targets improved quality and cost efficiency in contrast media production.
In preparation for tomorrow’s InvestorTalk, here are some recent news releases from Voyageur Pharmaceuticals for your review, which are listed below:
- March 25, 2026 – Voyageur Announces Non-Brokered Life Offering — click here
- March 16, 2026 – Voyageur Announces Advancements on its Barium & Iodine Contrast Media Projects – click here
- March 4, 2026 – Voyageur Pharmaceuticals Confirms Pharmaceutical-Grade Purity of Barite from Frances Creek and Progresses to Health Canada Human Trial with Alberta Innovates Grant; Announces Stock Option and DSU grants, and Proposed Issuance of Securities for Debt – click here
- February 23, 2026 – Voyageur Pharmaceuticals Announces Collaboration with Bayer – click here
We found the March 16th news release titled, “Voyageur Announces Advancements on its Barium & Iodine Contrast Media Projects” particularly noteworthy and here are 5 key data points from it:
- Dual BFS Strategy Underway – Voyageur Pharmaceuticals Ltd. is advancing two bankable feasibility studies for its radiology drug manufacturing project and the Bayer iodine project, forming the foundation of its vertically integrated strategy.
- Frances Creek Barium Project Advancing – The Frances Creek project hosts 132,000 tonnes of pharmaceutical-grade barium sulfate (98.8% purity) and is currently in the BFS stage, targeting completion in H2 2026.
- Initial Commercial Validation Achieved – Voyageur has generated approximately C$32,000 in early product sales from its Health Canada-approved barium contrast products, supporting market validation and pricing insights.
- U.S. FDA Approval Process Initiated – The Company has begun the FDA approval process (505(b)(2) pathway) for its barium products, with potential U.S. market entry targeted for 2027.
- Iodine Production and Strategic Partnership – Voyageur is advancing iodine production targeting 35 million doses annually, alongside a US$2.35M-supported Bayer iodine project, with potential future offtake-linked financing.
For more information on Voyageur Pharmaceuticals Ltd., click here
For more information on the InvestorTalk pre-market series, go to InvestorTalk.com.
Leave a Reply